RPL18, CPTAC-432 - CPTAC Assay Portal (original) (raw)

Please include the following statement when referencing the CPTAC Assay Portal

We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Protein Sequence hover to view complete sequence

CPTAC-432: View additional TNRPPLSLSR data

10 20 30 40 50
MGVDIRHNKD RKVRRKEPKS QDIYLRLLVK LYRFLARRTN STFNQVVLKR
60 70 80 90 100
LFMSRTNRPP LSLSRMIRKM KLPGRENKTA VVVGTITDDV RVQEVPKLKV
110 120 130 140 150
CALRVTSRAR SRILRAGGKI LTFDQLALDS PKGCGTVLLS GPRKGREVYR
160 170 180 188
HFGKAPGTPH SHTKPYVRSK GRKFERARGR RASRGYKN

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node

to view detailed assay information below

All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader


Assay Details for CPTAC-433 Collapse assay details

Data source: Panorama

Official Gene Symbol

RPL18

Peptide Sequence

ILTFDQLALDSPK

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

120

Peptide End

132

CPTAC ID

CPTAC-433

Peptide Molecular Mass

1,459.7922

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Broad Institute and FHCRC

Submitting Lab PI

Steve Carr


Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y11 (1+) | 9.8 | 10.5 | 7.4 | 14 | 14.3 | 16.4 | 17.1 | 17.7 | 18 | 25 | 15 | 15 | | y10 (1+) | 7.9 | 7 | 4.4 | 9.5 | 8.2 | 7 | 12.4 | 10.8 | 8.3 | 25 | 15 | 15 | | y9 (1+) | 7.1 | 7.3 | 2.3 | 8.2 | 7.4 | 8 | 10.8 | 10.4 | 8.3 | 25 | 15 | 15 | | sum | 7.5 | 7.7 | 4.2 | 9.7 | 9.8 | 10.4 | 12.3 | 12.5 | 11.2 | 25 | 15 | 15 |



Additional Resources and Comments


Assay Details for CPTAC-432 Collapse assay details

Data source: Panorama

Official Gene Symbol

RPL18

Peptide Sequence

TNRPPLSLSR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

56

Peptide End

65

CPTAC ID

CPTAC-432

Peptide Molecular Mass

1,139.6411

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Broad Institute and FHCRC

Submitting Lab PI

Steve Carr


Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y6 (1+) | 15.1 | 12.9 | 5.5 | 27.9 | 20.7 | 27.9 | 31.7 | 24.4 | 28.4 | 15 | 25 | 15 | | y5 (1+) | 9.6 | 9.9 | 6.2 | 9.9 | 13.9 | 13.7 | 13.8 | 17.1 | 15 | 15 | 25 | 15 | | y4 (1+) | 2 | 7.1 | 4.4 | 8.9 | 11 | 11.7 | 9.1 | 13.1 | 12.5 | 15 | 25 | 15 | | sum | 2.6 | 7.3 | 4.1 | 9 | 11.3 | 12.1 | 9.4 | 13.5 | 12.8 | 15 | 25 | 15 |



Additional Resources and Comments